Drug factory · FDA FEI 3006272184

Vistin Pharma AS avd Kragerø Fikkjebakke

Kragerø Næringspark Stuttlidalen 4, Sannidal, Norway

Norway: 1

Problems found, fixed voluntarily at FDA's last inspection, Jan 31, 2025.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

4 drug inspections on record since 2011: 0 with no problems, 4 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
Linagliptin and MetforminMakes the active ingredient Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0146, 0597-0147, 0597-0148

FDA inspection history

EndedResultProgramProblems noted
Jan 31, 2025Problems found, fixed voluntarilyDrug Quality Assurance—
May 24, 2019Problems found, fixed voluntarilyDrug Quality Assurance—
Jul 4, 2014Problems found, fixed voluntarilyDrug Quality Assurance—
Jun 7, 2011Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: analysis; api manufacture; manufacture.